Semaglutide cuts heavy drinking days in small alcohol trial

Semaglutide, the active ingredient in the in-demand diabetes drug Ozempic, reduced heavy drinking days and alcohol-related harm in a phase 2 clinical trial of people with alcohol use disorder. The post Semaglutide cuts heavy drinking days in small alcohol trial appeared first on…

Read the full story at The Drinks Business →

This is an aggregated headline. Full reporting and analysis lives at the source. Package Store credits and links the original publication on every aggregated story. See our editorial standards for how we handle sourcing.